Exonate Ltd (@exonateuk) 's Twitter Profile
Exonate Ltd

@exonateuk

Exonate is a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases.

ID: 2888324704

linkhttp://www.exonate.com calendar_today22-11-2014 20:50:27

555 Tweet

396 Followers

1,1K Following

Exonate Ltd (@exonateuk) 's Twitter Profile Photo

It was a pleasure to be selected to take part in a panel discussion yesterday at #BioTrinity. Alongside a renowned group of #lifescience leaders, Dr Catherine Beech provided insight into the dynamic landscape of leadership within an early-stage life science company.

It was a pleasure to be selected to take part in a panel discussion yesterday at #BioTrinity.

Alongside a renowned group of #lifescience leaders, Dr Catherine Beech provided insight into the dynamic landscape of leadership within an early-stage life science company.
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

This May, join us raising awareness for #HealthyVisionMonth, organised by NEI. The focus for 2024 is the impact that #visionloss has on #mentalhealth, and raising awareness of the support services available to help patients. Find out more: rb.gy/lonu7m

This May, join us raising awareness for #HealthyVisionMonth, organised by <a href="/NatEyeInstitute/">NEI</a>. The focus for 2024 is the impact that #visionloss has on #mentalhealth, and raising awareness of the support services available to help patients.  Find out more: rb.gy/lonu7m
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

We had a fantastic time last week in Seattle for #ARVO2024! It was great to meet experts working across all aspects of #ophthalmology. We’re grateful for the opportunity to present #clinicaltrial data on EXN407, our novel, topical therapy for diabetic #macularedema.

We had a fantastic time last week in Seattle for #ARVO2024!

It was great to meet experts working across all aspects of #ophthalmology. We’re grateful for the opportunity to present #clinicaltrial data on EXN407, our novel, topical therapy for diabetic #macularedema.
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

🎉Our team had a fantastic evening at the Cambridge Independent Science and Technology Awards ceremony! We are proud to have been recognised as a finalist alongside such an impressive array of companies - congratulations to all the finalists and winners!

🎉Our team had a fantastic evening at the <a href="/CambridgeIndy/">Cambridge Independent</a> Science and Technology Awards ceremony!

We are proud to have been recognised as a finalist alongside such an impressive array of companies - congratulations to all the finalists and winners!
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

Today we celebrate #ClinicalTrialsDay! Organised by ACRP - Assoc. of Clinical Research Profession, 20th May provides a moment for reflection, recognition, and admiration for the achievements made possible by clinical trials and the people behind them. Visit: clinicaltrialsday.org/about

Today we celebrate #ClinicalTrialsDay!

Organised by <a href="/ACRPDC/">ACRP - Assoc. of Clinical Research Profession</a>, 20th May provides a moment for reflection, recognition, and admiration for the achievements made possible by clinical trials and the people behind them. 

Visit: clinicaltrialsday.org/about
Zyme Communications (@zymecomms) 's Twitter Profile Photo

This morning Exonate Ltd announced the appointment of Dr Rafiq Hasan as Non-Executive Director, bringing extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses. More: shorturl.at/EsbBJ

This morning <a href="/ExonateUK/">Exonate Ltd</a> announced the appointment of Dr Rafiq Hasan as Non-Executive Director, bringing extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.

More: shorturl.at/EsbBJ
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

We’re pleased to welcome Dr Rafiq Hasan to our Board. Rafiq’s extensive knowledge of the #ophthalmology sector and treatment strategies for diabetic eye disease will help to guide our strategy as we progress towards our CLEAR-DE phase IIb #clinical trial: rb.gy/nweo7p

We’re pleased to welcome Dr Rafiq Hasan to our Board.

Rafiq’s extensive knowledge of the #ophthalmology sector and treatment strategies for diabetic eye disease will help to guide our strategy as we progress towards our CLEAR-DE phase IIb #clinical trial: rb.gy/nweo7p
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

Congratulations to Professor Robyn Guymer on being named in The Ophthalmologist's 2024 Power List! We're honoured to have Professor Guymer on our Clinical Advisory Board, supporting our mission to transform the lives of those suffering from #visionloss. More: rb.gy/fihklk

Congratulations to Professor Robyn Guymer on being named in <a href="/OphthoMag/">The Ophthalmologist</a>'s 2024 Power List!

We're honoured to have Professor Guymer on our Clinical Advisory Board, supporting our mission to transform the lives of those suffering from #visionloss.

More: rb.gy/fihklk
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

June is #VisionResearchMonth! Join us in raising awareness as researchers, doctors, and advocates come together to bring the latest advancements in eye health to the forefront.

June is #VisionResearchMonth! Join us in raising awareness as researchers, doctors, and advocates come together to bring the latest advancements in eye health to the forefront.
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

Diabetes is one of the most prevalent chronic diseases worldwide. During #DiabetesWeek, help raise awareness and highlight the issues that matter to those living with diabetes. diabetes.org.uk/diabetes-week

Diabetes is one of the most prevalent chronic diseases worldwide. During #DiabetesWeek, help raise awareness and highlight the issues that matter to those living with diabetes.

diabetes.org.uk/diabetes-week
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

Macular Week 2024 starts this Monday. Diseases involving the macular, such as diabetic eye disease, are amongst the leading causes of #visionloss. We're proud to support raising awareness for these diseases, and the critical need to develop new, effective treatments.

Macular Week 2024 starts this Monday. 
 
Diseases involving the macular, such as diabetic eye disease, are amongst the leading causes of #visionloss. We're proud to support raising awareness for these diseases, and the critical need to develop new, effective treatments.
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

We’ve been shortlisted for the #BusinessWeeklyAwards! We’re honoured to have made the shortlist along with other companies in the Cambridge cluster pioneering research across #lifescience, #tech and beyond. Read the full shortlist Business Weekly: rb.gy/rxea6m

We’ve been shortlisted for the #BusinessWeeklyAwards!

We’re honoured to have made the shortlist along with other companies in the Cambridge cluster pioneering research across #lifescience, #tech and beyond.

Read the full shortlist <a href="/businessweekly/">Business Weekly</a>: rb.gy/rxea6m
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

Are you attending Ophthalmology Futures. In September we’ll in Barcelona for the Retina Forum, meeting alongside other global ophthalmology experts. We're also excited to announce that we will be presenting at the event. #off2024 #ophthalmicinnovation

Are you attending Ophthalmology Futures. In September we’ll in Barcelona for the Retina Forum, meeting alongside other global ophthalmology experts. We're also excited to announce that we will be presenting at the event.

#off2024 #ophthalmicinnovation
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

We're pleased to announce plans to progress our lead candidate to a Phase IIb 'CLEAR-DE' clinical trial, to further validate EXN407 for clinical efficacy, optimal dosing and safety in patients with non-proliferative diabetic retinopathy. Read more: bit.ly/3U3TWIq

We're pleased to announce plans to progress our lead candidate to a Phase IIb 'CLEAR-DE' clinical trial, to further validate EXN407 for clinical efficacy, optimal dosing and safety in patients with non-proliferative diabetic retinopathy.

Read more: bit.ly/3U3TWIq
Exonate Ltd (@exonateuk) 's Twitter Profile Photo

We are honoured and thrilled  to announce that we have won the OBN awards Best Established Company 2025. Congratulations to all of the finalists and winners, a truly inspirational evening.#OBNawards #lifescience #lifesciencesawards

We are honoured and thrilled  to announce that we have won the OBN awards Best Established Company 2025. Congratulations to all of the finalists and winners, a truly inspirational evening.#OBNawards #lifescience #lifesciencesawards